Business UpdateMay 27, 2026, 08:02 AM
Avalyn Pharma to Present at Jefferies Global Healthcare Conference
AI Summary
Avalyn Pharma Inc. announced that its management will present a company overview at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will detail the company's progress in pioneering inhaled therapies for serious, rare respiratory diseases, including its AP01, AP02, and AP03 programs. A live webcast and archived recording of the event will be accessible via the investor section of Avalyn Pharma's website.
Key Highlights
- Avalyn Pharma management to present a company overview at the Jefferies Global Healthcare Conference.
- The presentation is scheduled for June 4, 2026, from 9:55-10:25 a.m. ET.
- Avalyn is advancing optimized inhaled formulations for pulmonary fibrosis and rare respiratory diseases.
- AP01 program is in a global Phase 2b clinical trial (MIST) for progressive pulmonary fibrosis.
- AP02 program is in a global Phase 2 clinical trial (AURA-IPF) for idiopathic pulmonary fibrosis.
- AP03 program is an inhaled fixed-dose combination of pirfenidone and nintedanib.
- A live webcast and archived recording will be available on the company’s investor relations website.
Price Impact
More from AVLN